Victory Capital Management Inc Avrobio, Inc. Transaction History

Victory Capital Management Inc

$95.7 Billion
Q4 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 02, 2021	SELL	$5.53 - $9.28 $605,313 - $1.02 Million	-109,460 Closed	0 $0
Q2 2021 Aug 03, 2021	SELL	$7.84 - $12.6 $163,150 - $262,206	-20,810 Reduced 15.97%	109,460 $973,000
Q1 2021 May 04, 2021	BUY	$10.54 - $19.3 $334,328 - $612,196	31,720 Added 32.19%	130,270 $1.65 Million
Q4 2020 Feb 01, 2021	SELL	$12.79 - $17.1 $228,557 - $305,577	-17,870 Reduced 15.35%	98,550 $1.37 Million
Q3 2020 Nov 09, 2020	SELL	$12.99 - $19.41 $507,688 - $758,601	-39,083 Reduced 25.13%	116,420 $1.52 Million
Q2 2020 Aug 07, 2020	SELL	$12.19 - $22.96 $3.41 Million - $6.41 Million	-279,330 Reduced 64.24%	155,503 $2.71 Million
Q1 2020 May 04, 2020	BUY	$10.08 - $27.21 $174,222 - $470,297	17,284 Added 4.14%	434,833 $6.77 Million
Q4 2019 Feb 06, 2020	SELL	$13.05 - $21.88 $373,921 - $626,927	-28,653 Reduced 6.42%	417,549 $8.41 Million
Q4 2019 Feb 04, 2020	SELL	$13.05 - $21.88 $446,662 - $748,886	-34,227 Reduced 7.12%	446,202 $9.7 Million
Q3 2019 Nov 12, 2019	BUY	$14.12 - $23.44 $5.19 Million - $8.61 Million	367,358 Added 324.89%	480,429 $6.78 Million
Q2 2019 Aug 15, 2019	SELL	$13.21 - $27.29 $312,944 - $646,500	-23,690 Reduced 17.32%	113,071 $1.84 Million
Q1 2019 May 03, 2019	BUY	$12.46 - $22.05 $1.67 Million - $2.95 Million	133,860 Added 4614.27%	136,761 $3.02 Million
Q4 2018 Feb 05, 2019	SELL	$15.43 - $32.7 $8,532 - $18,083	-553 Reduced 16.01%	2,901 $48,000
Q3 2018 Nov 01, 2018	BUY	$26.95 - $52.7 $12,235 - $23,925	454 Added 15.13%	3,454 $179,000
Q2 2018 Aug 02, 2018	BUY	$28.08 - $31.2 $84,240 - $93,600	3,000 New	3,000 $86,000

Others Institutions Holding AVRO

# of Institutions

Shares Held

559K

Call Options Held

Put Options Held

Terrapin Asset Management, LLC Miami, FL

559K
Shares

$0
0.98% of portfolio

View Full List

About AVROBIO, Inc.

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

More about AVRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account